ClinicalTrials.gg
DrugRead study by study

Imlunestrant clinical trials

Also written LY3484356.

studies test it
15
open now
5
in phase 3
2
first study started
2019
ClinicalTrials.gov finds 21 studies for Imlunestrant. How that becomes 15 here

Every study that search finds has been read, to see whether and how it gives Imlunestrant. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 21Found by its intervention search · See all 21 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 15 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. 21Give Imlunestrant to participants
  3. −6Give it beside what is tested
  4. 15Test it: the count on this site

Get an email when these change. Save the Imlunestrant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
25 Sept 2025 · INLURIYO · NDA 218881 (FDA, Drugs@FDA)
European Union
9 Jan 2026 · Inluriyo · EMEA/H/C/006184 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Imlunestrant
10

Development codes

LY3484356
13

Studies by the year they started

15 studies that test it; most in 2022 (5)

Studies that test Imlunestrant, by start year
YearStudies
20191
20214
20225
20265

By phase

A phase 1/2 study counts in both.

Phase 1
9
Phase 2
4
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 3

Eli Lilly and Company (12) · Dana-Farber Cancer Institute (1) · Fudan University (1) · Jonsson Comprehensive Cancer Center (1)

Often tested with

Tested in the same studies.

Abemaciclib (3) · Carbamazepine (1) · Omeprazole (1) · Selinexor (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 3 most studied

New when their studies opened, with Imlunestrant beside them; studies of each.

Reaching primary completion within a year · 2, 1 in phase 3

Studies that test Imlunestrant, phase 3 first.

Studies

Open first, then newest update. How each study uses Imlunestrant has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 15

Behind its US label · 1 — the studies the FDA label of INLURIYO describes

From the Clinical Studies section of INLURIYO (2026-06), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 5 — no other medicine in its arm
Tested with established drugs · 5 — they are given beside it
Tested in a combination · 5 — another drug in the study is under test too
Beside a new treatment under test · 3 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with Imlunestrant: Mutant-selective PI3K-alpha H1047R Inhibitor LOXO-783 1 · PRT13722 1 · STX-478 1

One option of several · 3 — a test or a strategy chooses among drugs

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call Imlunestrant · ClinicalTrials.gg INT001724

  • MeSH (NLM) C000719756ImlunestrantConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 9CXQ3PF69UIMLUNESTRANTConfirmed FDA, NLM, Wikidata
  • Wikidata Q123582076imlunestrantConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C174042ImlunestrantOne source FDA
  • DrugBank DB19043One source Wikidata

Also registered as imlunestrant tosylate (UNII F7UDT90EW5).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion